These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37823328)

  • 21. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
    Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
    Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.
    Vely A; Paillassa J; Nunes Gomes C; Giltat A; Fouquet S; Lebreton A; Klemencie M; Clavert A; Tanguy-Schmidt A; Hunault-Berger M; Orvain C
    Ann Hematol; 2023 Aug; 102(8):2225-2231. PubMed ID: 37380715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
    Vély A; Couturier MA; Delepine P; Le Calloch R; Ertault M; Gastinne T; Plichon C; Lebreton A; Lester MA; Larhantec G; Cormier N; Fouquet S; Houot R; Tanguy-Schmidt A; Hunault-Berger M; Orvain C
    Leuk Lymphoma; 2023 Dec; 64(13):2178-2187. PubMed ID: 37615123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
    Zhang L; Yang H; Qian C; Zhou J; Zhu Q; Jiang Y; Liu S; Chen X; Xu T; Qu C; Li C; Jin Z; Chu J; Zhang X; Wu D; Huang H
    Hematology; 2022 Dec; 27(1):404-411. PubMed ID: 35413224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
    Vokurka S; Bystricka E; Scudlova J; Mazur E; Visokaiova M; Vasilieva E; Brandejsova R; Chvojkova I; Vrabcova M; Vitkova J; Mjartanova D; Vodickova M; Bockova J; Streinerova K
    Eur J Oncol Nurs; 2011 Dec; 15(5):508-12. PubMed ID: 21310656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
    Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
    Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
    Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
    Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
    Meyer A; Fornecker LM; Guffroy A; Korganow AS; Martin M
    Rev Med Interne; 2018 Nov; 39(11):882-885. PubMed ID: 29673920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
    Esbah O; Tekgündüz E; Şirinoğlu Demiriz I; Civriz Bozdağ S; Kaya A; Tetik A; Kayıkçı Ö; Durgun G; Kocubaba Ş; Altuntaş F
    Turk J Haematol; 2016 Sep; 33(3):209-15. PubMed ID: 26377357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term thyroid disorders in pediatric survivors of hematopoietic stem cell transplantation after chemotherapy-only conditioning.
    Cima LN; Martin SC; Lambrescu IM; Stejereanu L; Zaharia C; Colita A; Fica S
    J Pediatr Endocrinol Metab; 2018 Aug; 31(8):869-878. PubMed ID: 29935114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
    Khattry N; Gupta A; Jain R; Gore A; Thippeswamy R; Jeevangi N; Kannan S; Nair R; Saikia T
    Int J Hematol; 2016 Mar; 103(3):292-8. PubMed ID: 26729297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.